Nurix Therapeutics, Inc.
For the period ended Aug 31, 2026. Filed Oct 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Aug 31, 2026 · Filed Oct 13, 2026
NRIX$16.14+5.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| August 31,2026 | November 30,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $720,242 | $246,960 |
| Marketable securities, current | 328,013 | 345,981 |
| Accounts receivable | 20,000 | — |
| Prepaid expenses and other current assets | 35,437 | 13,878 |
| Total current assets | 1,103,692 | 606,819 |
| Marketable securities, non‑current | 14,832 | — |
| Operating lease right-of-use assets | 48,631 | 50,517 |
| Property and equipment, net | 19,407 | 22,490 |
| Restricted cash | 782 | 968 |
| Other assets | 7,954 | 7,341 |
| Total assets | $1,195,298 | $688,135 |
| Liabilities and stockholdersʼ equity | ||
| Current liabilities: | ||
| Accounts payable | $32,984 | $11,215 |
| Accrued expenses and other current liabilities | 63,674 | 54,852 |
| Operating lease liabilities, current | 3,241 | 2,824 |
| Deferred revenue, current | 8,610 | 17,580 |
| Deferred collaboration funding, current | 22,233 | — |
| Total current liabilities | 130,742 | 86,471 |
| Operating lease liabilities, net of current portion | 62,091 | 52,906 |
| Deferred revenue, net of current portion | 10,778 | 10,011 |
| Deferred collaboration funding, net of current portion | 23,376 | — |
| Total liabilities | 226,987 | 149,388 |
| Commitments and contingencies (Note 6) | ||
| Stockholdersʼ equity: | ||
| Preferred stock, $0.001 par value— 10,000,000 shares authorized as of August 31, 2026 and November 30, 2025; no shares issued and outstanding as of August 31, 2026 and November 30, 2025 | — | — |
| Common stock, $0.001 par value— 500,000,000 shares authorized as of August 31, 2026 and November 30, 2025; 109,200,394 and 101,807,484 shares issued and outstanding as of August 31, 2026 and November 30, 2025, respectively | 109 | 102 |
| Additional paid-in capital | 1,598,540 | 1,541,766 |
| Accumulated other comprehensive income (loss) | (210) | 105 |
| Accumulated deficit | (630,128) | (1,003,226) |
| Total stockholdersʼ equity | 968,311 | 538,747 |
| Total liabilities and stockholdersʼ equity | $1,195,298 | $688,135 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.